TKELLEY on DSK3SPTVN1PROD with NOTICES

Federal Register / Vol. 77, No. 130 / Friday, July 6, 2012 / Notices 40059 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

notices are set forth in paragraph 7 of 

the Act (12 U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the offices of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than July 16, 

2012. 

A. Federal Reserve Bank of 

Minneapolis (Jacqueline G. King, 

Community Affairs Officer) 90 

Hennepin Avenue, Minneapolis, 

Minnesota 55480–0291: 

1. Thomas Watson, Grand Forks, 

North Dakota, as an individual and as 

trustee, and Thomas Watson and Toby 

Kommer, Fargo, North Dakota, as 

trustees of the Bank Forward Employee 

Stock Ownership Plan, Hannaford, 

North Dakota (‘‘ESOP’’), to acquire 

control of Security State Bank Holding 

Company, Fargo, North Dakota 

(‘‘Company’’), and thereby indirectly 

acquire control of Bank Forward, 

Hannaford, North Dakota. In addition, 

Mr. Watson and Mr. Kommer, and the 

ESOP, have applied as a group acting in 

concert to control Company. 

Board of Governors of the Federal Reserve 

System, June 29, 2012. 

Jennifer J. Johnson, 

Secretary of the Board. 

[FR Doc. 2012–16483 Filed 7–5–12; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Designation of a Class of Employees 

for Addition to the Special Exposure 

Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice of a 

decision to designate a class of 

employees from the Feed Materials 

Production Center (FMPC) in Fernald, 

Ohio, also known as the Fernald 

Environmental Management Project 

(FEMP), as an addition to the Special 

Exposure Cohort (SEC) under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000. On 

June 27, 2012, the Secretary of HHS 

designated the following class of 

employees as an addition to the SEC: 

All employees of DOE, DOE contractors, or 

subcontractors who worked at all locations at 

the Feed Materials Production Center (FMPC) 

in Fernald, Ohio, also known as the Fernald 

Environmental Management Project (FEMP), 

from January 1, 1968, through December 31, 

1978, for a number of work days aggregating 

at least 250 work days, occurring either 

solely under this employment or in 

combination with work days within the 

parameters established for one or more 

classes of employees included in the Special 

Exposure Cohort. 

This designation will become effective 

on July 27, 2012, unless Congress 

provides otherwise prior to the effective 

date. After this effective date, HHS will 

publish a notice in the Federal Register 

reporting the addition of this class to the 

SEC or the result of any provision by 

Congress regarding the decision by HHS 

to add the class to the SEC. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

NIOSH, 4676 Columbia Parkway, MS C– 

46, Cincinnati, OH 45226, Telephone 1– 

877–222–7570. Information requests can 

also be submitted by email to DCAS@ 

CDC.GOV. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2012–16591 Filed 7–5–12; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

has taken final action in the following 

case: 

Sinae Kim, Ph.D., Emory University: 

Based on the report of an investigation 

conducted by Emory University (EU) 

and additional analysis conducted by 

ORI in its oversight review, ORI found 

that Dr. Sinae Kim, former Postdoctoral 

Fellow, Department of Medicine, EU, 

engaged in research misconduct in 

research supported by National Heart, 

Lung, and Blood Institute (NHLBI), 

National Institutes of Health (NIH), 

grants R01 HL079137, R01 HL084471, 

and R03 HL096325, and National 

Institute of General Medical Sciences 

(NIGMS), NIH, grant RC1 GM092035. 

FOR FURTHER INFORMATION CONTACT: John 

Dahlberg, Ph.D., Director, Division of 

Investigative Oversight, Office of 

Research Integrity, 1101 Wootton 

Parkway, Suite 750, Rockville, MD 

20852, (240) 453–8800. 

SUPPLEMENTARY INFORMATION: ORI found 

that the Respondent engaged in research 

misconduct by falsifying data that were 

included in five (5) manuscripts 

submitted in 2009 for publication to 

Blood, Nature, Nature Biotechnology, 

Nature Medicine, and Science, one (1) 

poster presented at the 2009 American 

Heart Association (AHA) meeting, four 

(4) laboratory meeting presentations, 

one (1) image file, three (3) funded NIH 

grants (RC1 GM092035, R01 HL079137, 

and R03 HL096325), and five (5) 

submitted NIH grant applications (RC1 

HL100648–01, RC2 HL101600–01, RC4 

HL106748-01, R01 HD067130–01, and 

U01 HL107444–01). The manuscripts 

submitted in 2009 were not accepted for 

publication. 

Specifically, ORI finds that the 

Respondent knowingly and 

intentionally: 

1. Falsified three (3) figures for 

immunocytochemistry and alkaline 

phosphtase (AP) staining images, 

karyotyping and real-time reverse 

transcription polymerase chain reaction 

(RT–PCR) results by using experimental 

results from her prior work in Korea 

with human embryonic stem cells 

(hESCs) to confirm the generation, 

differentiation, and verification of 

human induced pluripotent stem cells 

(iPSCs). The false data were included in: 

a. Figures 1c and 2i (panels #4 & 13) in 

the Nature 2009, Science 2009, and 

Nature Biotechnology 2009 

manuscripts and Supplementary 

Figure 4 in the Nature 2009 

manuscript 

b. Supplementary Figure 5 in the Nature 

Biotechnology 2009 manuscript 

c. Figures S1B and S1D (panels #4 & 13) 

in the Blood 2009 manuscript 

d. Supplementary Figures 8B and 8D 

(panels #4 & 13) in the Nature 

Medicine 2009 manuscript 

e. Figure 9 in the RC1 GM092035 grant 

f. Figure 8 in the R01 HL079137 grant 

g. Figure 2 in the RC1 HL100648 grant 

h. Figure 8 in the RC2 HL101600 grant 

i. Figure 3 in the R01 HD067130 grant 

j. Figure 1 in the RC4 HL106748 grant 

k. Figures 1C, 1H, and 1I (panel #3) in 

the R03 HL096325 grant 

l. Figure 5 in the U01 HL107444 grant 

m. Figures 2C and 3I (panels #4 & 13) 

in the poster presented at the 2009 

AHA meeting 

n. The presentations ‘Figures_Sinae 

Kim_120808.ppt’ and ‘Figures_Sinae 

Kim_121508.ppt’